Benzinga · Sep 23, 2026
Anthropic, Kalshi and Polymarket Before Their IPOs? ETFs Are Finding a Way in
Tema ETFs is offering pre-IPO exposure to Anthropic, Kalshi and Polymarket through ETFs, using SPVs to access private-market names.
DI
NASDAQ · DICE
DICE Therapeutics, Inc.
Healthcare · Biotechnology
$24.38
Up+$0.03 (+0.06%)
Updated Oct 7, 2026, 9:30 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.27B
- P/E ratio
- -22.94
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 1.75K
- Avg. volume
- 1.91M
Price performance · DICE
DICE price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
DICE closed at $24.38 after 20 trading sessions, down 3.09% for the selected period.
- Last close
- $24.38
- Period change
- -3.09%
- Period low
- $23.72
- Period high
- $26.01
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $24.59 | $24.59 | $24.3834 | $24.3834 | 1.75K |
| Oct 5, 2026 | $24.46 | $24.46 | $24.3825 | $24.3825 | 727.33 |
| Oct 2, 2026 | $24.11 | $24.13 | $24.07 | $24.0814 | 888.91 |
| Oct 1, 2026 | $24.64 | $24.71 | $24.5803 | $24.5803 | 1.72K |
| Sep 30, 2026 | $24.80 | $24.80 | $24.6524 | $24.6524 | 6.19K |
| Sep 29, 2026 | $24.59 | $25.19 | $24.59 | $24.8505 | 16.7K |
| Sep 28, 2026 | $25.34 | $25.34 | $24.9971 | $24.9971 | 4.57K |
| Sep 25, 2026 | $25.28 | $25.42 | $25.2178 | $25.3267 | 1.76K |
| Sep 24, 2026 | $25.87 | $25.87 | $25.56 | $25.7228 | 936.34 |
| Sep 23, 2026 | $26.16 | $26.16 | $25.6485 | $25.6485 | 989.84 |
| Sep 22, 2026 | $26.03 | $26.03 | $25.88 | $26.0076 | 1.48K |
| Sep 21, 2026 | $25.8499 | $26.0057 | $25.80 | $26.0057 | 2.75K |
| Sep 18, 2026 | $25.09 | $25.3978 | $25.09 | $25.3978 | 951.16 |
| Sep 17, 2026 | $24.15 | $24.30 | $24.12 | $24.2627 | 2.72K |
| Sep 16, 2026 | $25.00 | $25.00 | $23.7209 | $23.7209 | 1.88K |
| Sep 15, 2026 | $25.00 | $25.00 | $24.20 | $24.218 | 5.33K |
| Sep 14, 2026 | $25.00 | $25.15 | $24.835 | $25.0471 | 7.07K |
| Sep 11, 2026 | $24.94 | $25.00 | $24.8311 | $24.8311 | 2.12K |
| Sep 10, 2026 | $25.29 | $25.29 | $24.8379 | $24.8379 | 2.14K |
| Sep 9, 2026 | $25.69 | $25.69 | $25.1615 | $25.1615 | 681 |
Latest DICE news
The latest Smart Investors Daily articles mentioning DICE.
Stock researchCompany · Overview
Company
Market Activity
Research & News
DICE research
Overview
Company profile and research snapshot.
Company profile
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVß1/aVß6 integrin for the treatment of idiopathic pulmonary fibrosis. In addition, the company focuses on immuno-oncology for antibody therapeutics. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Hold
- Average target
- $60.00
- Implied upside
- —
- Analysts
- 14
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 9, 2023 | HC Wainwright & Co. | Neutral | — |
| Jun 26, 2023 | Needham | Hold | — |
| Jun 21, 2023 | Canaccord Genuity | Hold | — |
| Jun 21, 2023 | HC Wainwright & Co. | Neutral | — |
| Jun 20, 2023 | Canaccord Genuity | Hold | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 22, 2026
This Bonkers ETF Market: The Zine Edition
The ETF market is experiencing change at a monumental pace, and some of those changes may actually be hurting you and your clients. Dave Nadig breaks down the current state of the industry, pulled from the zine he made for the ETF Oasis at Future Proof, that touches on everything from buffered ETFs to sports betting and deregulation.
SeekingAlpha · Sep 22, 2026
Get Kalshi And Polymarket Exposure With These ETFs
Get public exposure to prediction markets like Kalshi & Polymarket via ETFs XOVR, TOLL, and DICEâcompare allocations, liquidity risks, and act now. Click for more.
Yahoo · Sep 12, 2026
Kalshi and Polymarket Aren’t Public. You Still Buy Them Through an ETF.
A handful of funds have pre-IPO exposure to Kalshi and Polymarket. Investors need to tread cautiously.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
